EcoDrugPlus

Histone Deacetylase 7

Ensembl ID : ENSOTSG00005018441
Gene Symbol: HDAC7
1 Cross references
184 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSOTSG00005018034
Gene Symbol: HDAC8
1 Cross references
204 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOTSG00005029339
Gene Symbol: HCN4
1 Cross references
214 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOTSG00005011236
Gene Symbol: HCN4
1 Cross references
210 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOTSG00005040740
Gene Symbol: HCN4
1 Cross references
214 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSOTSG00005011825
Gene Symbol: HCRTR2
1 Cross references
203 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSOTSG00005011560
Gene Symbol: IKBKB
1 Cross references
195 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSOTSG00005031066
Gene Symbol: IMPDH1
3 Cross references
250 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSOTSG00005025796
Gene Symbol: IMPDH1
1 Cross references
251 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSOTSG00005032197
Gene Symbol: LOC112252448
3 Cross references
250 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 2-Like

Ensembl ID : ENSOTSG00005026833
Gene Symbol: LOC112238035
3 Cross references
194 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSOTSG00005020317
Gene Symbol: INSR
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).